cagrisema phase 3 results 2025 semaglutide cagrilintide obesity is one of the most #potent #weightloss medication developed till date! Cagrisema on an average causes 9% additional weight loss over # 2.4mg/week! Cagrisema is a fixed-dose combination of semaglutide 2.4mg + # Updates in Medicine | 🔬

It's important to note that there are currently supply constraints for GLP-1 receptor agonists in the UK, and NHS England advises against using Ozempic off-label for weight management to ensure availability for diabetes patients

doi:10.1371/journal.pone.0033944 Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ et al (2002) Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial

Inhalation is a significant exposure route, with some studies reporting no adverse effects, while others observed pulmonary inflammation, altered lung function, and neurotoxicity [234]

Ive had zero side effects

Experiments conducted in the United Kingdom were performed in accordance with the UK Animals (Scientific Procedures) Act 1986, and experimental protocols were approved by the UCL Animal Welfare and Ethical Review Body (Bloomsbury Campus)